Novartis opens global production facility for innovative retina drug in Tyrol

Starting in 2021, Novartis will exclusively produce a new retina drug at its Tyrolean plant in Kundl, designed to combat wet age-related macular degeneration.

The Swiss pharmaceutical company Novartis recently announced that it launched a global production facility for innovative retina drug ingredients at its site in Kundl, Tyrol. The company invested a total of about USD 30 million (or approx. EUR 27.4 million) for this purpose. The production of active pharmaceutical ingredients will take place simultaneously in both Switzerland and Tyrol. The plant in Kundl will be expanded by the beginning of 2021 to gradually service as the exclusive production centre and will also assume sole responsibility for global deliveries. "This substance is a humanised single-chain antibody fragment whose production requires top-class know-how. In this way, Novartis in Austria is once again demonstrating its innovative strength", explained Michael Kocher, Novartis Country President, and Mario Riesner, Plant Manager in Kundl.

The substance will be used within the context of a therapy for a widespread disease of the retina (wet age-related macular degeneration) and was approved by European authorities in February 2020. A team of up to 40 specialists of the Novartis Technical Operations Network is working in three shifts Tyrol to manufacture the antibody fragment in line with the highest quality and safety standards. "The investments in the global production of this new substance underline the central role played by the Austrian sites in the global Novartis network. It is a strong commitment, and we are convinced that we, the Austrian team here, will succeed in attracting further innovative drugs and their production to Tyrol", said Kocher and Riesner.

From a medical perspective, the experts expect a strong level of effectiveness of the substance in treating the areas of the retina affected by the pathological wetness. This was shown in the pivotal studies which took place in the USA and Europe. In turn, this could mean that patients will not have to undergo therapy as frequently. Two leading scientific centres in Austria participated in the pivotal studies, namely the University Eye Clinic of Vienna and the Medical University Eye Clinic in Graz, thus contributing to the further development of the substance. The Novartis sites in Kundl/Schattenau, Tyrol as well as the plant in Unterach am Attersee in Upper Austria also belong to the company's global network of research and development centres.

Click here to view the original article.

The information on this page may have been provided by a contributor to ChinaGoAbroad, and ChinaGoAbroad makes no guarantees about the accuracy of any content. All content shall be used for informational purposes only. Contributors must obtain all necessary licenses and/or ownership rights from the relevant content owner(s) before submitting such content (including texts, pictures, photos and diagrams) to ChinaGoAbroad for publication. ChinaGoAbroad disclaims all liability arising from the publication of any content/information (such as texts, pictures, photos and diagrams that infringe on any copyright) received from contributors. Links may direct to third party sites out of the control of ChinaGoAbroad, and such links shall not be considered an endorsement by ChinaGoAbroad of any information contained on such third party sites. Please refer to our Disclaimer for more details.